To develop a panel of monoclonal antibodies that will be used to develop sensitive immunoassays for detection of multiple serotypes of botulinum neurotoxin.
Approach:
Monoclonal anti-toxin antibodies for serotypes B and E will be developed using chemical cell fusion methods following immunization with toxoids, toxins, or recombinant peptides. In addition, antibodies to nontoxin associated proteins will be developed. The monoclonal antibodies will be supplied to DHS contractors and other collaborating federal laboratories in order to format sensitive immunoassays for toxin identification.